NCUK Research Publications

Jun 4, 2012

NET Patient Foundation Research Abstracts

NPF and NCRAS Public Health England partnership project has been compiling statistics on the incidence, prevalence and survival of NET patients in England using English cancer registry data, with an aim to also access Scottish, Welsh and Northern Irish cancer registry data to also get UK wide statistics.

We carried out four pieces of research in 2017, abstracts for which can be found below:

Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic Neuroendocrine tumours

The aims of this study were to establish pre-diagnosis patterns of symptoms. Secondly, to determine the time from onset of symptoms to NET diagnosis and understand the interaction with primary and secondary healthcare providers.

Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme

The aim of this study was to identify and characterize NETs diagnosed within the English BCSP, a double-screen programme that uses guaic faecal occult blood test (gFOBT) screening and colonoscopy, by interrogating the national colorectal screening database and validating the findings with individual BCSP centres.

Self-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues – the role for specialist dietitians and nurses

The aims of this study were to:

  • Assess what symptoms/side effects patients report on SSA’s.
  • Assess the severity of symptoms/side effects reported by patients whilst on SSA’s.
  • Produce recommendations on how to deal with symptoms commonly experienced by patients on SSA’s.

This study has been accepted to be published in the British Journal of Nursing.

Recent News

Mounjaro® (Tirzepatide) & Neuroendocrine Cancers

Mounjaro® (Tirzepatide) & Neuroendocrine Cancers

We have had a number of enquiries about the use of Mounjaro® (Tirzepatide) and similar medications (e.g. Wegovy®, etc) in individuals with neuroendocrine cancer. Here we provide a summary of information currently available, which we hope will address some of the...

read more
URGENT UPDATE 9TH JULY – Rare Cancers Bill

URGENT UPDATE 9TH JULY – Rare Cancers Bill

Update 11th July 2025 Delighted to see Dr Scott Arthur's Rare Cancers Bill pass through third reading in the House of Commons on Friday. This Bill is a crucial step forward for those living with rare and less common cancers. Thank You to everyone who contacted their...

read more
URGENT ACTION NEEDED – CHANGES TO PIP PROPOSED

URGENT ACTION NEEDED – CHANGES TO PIP PROPOSED

URGENT ACTION NEEDED  The impact of cancer is far more than medical. With it, comes a hidden and often devastating financial burden that many do not see or expect: the ripple effect extending to family members and carers. From travelling to receive the right treatment...

read more